Skip to main content
SpringerLink
Log in

High-Grade Astrocytomas

  • Chapter
  • First Online:
Primary Central Nervous System Tumors

Part of the book series: Current Clinical Oncology ((CCO))

  • 1506 Accesses

Abstract

High-grade astrocytomas (HGAs) are the most common adult primary malignant brain tumor, which include anaplastic astrocytoma (AA; World Health Organization [WHO] grade III) and glioblastoma multiforme (GBM; WHO grade IV). Although HGAs represent an overall uncommon cancer, they are associated with morbidity and high mortality. Despite state-of-the-art multimodality treatments, the median survival of GBM patients is 12–15 months, whereas that of AA is 2–3 years [1]. Current treatments for HGA include surgery, radiation, and chemotherapy. Temozolomide, an oral alkylating chemotherapy, has been approved for newly diagnosed GBM and recurrent AA. It offers significant, albeit modest, survival benefit for unselected HGA patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359:492–507.

    Article  CAS  PubMed  Google Scholar 

  2. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004–2006. Chicago:Central Brain Tumor Registry of the United States (CBTRUS); 2010.

    Google Scholar 

  3. Ron E, Modan B, Boice JD Jr et al. Tumors of the brain and nervous system after radiotherapy in childhood. N Engl J Med. 1988;319:1033–39.

    Article  CAS  PubMed  Google Scholar 

  4. Bondy ML, Scheurer ME, Malmer B et al. Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer 2008;113:1953–68.

    Article  PubMed  Google Scholar 

  5. Liu Y, Shete S, Hosking FJ et al. New insights into susceptibility to glioma. Arch Neurol. 2010;67:275–78.

    Article  PubMed  Google Scholar 

  6. Myung SK, Ju W, McDonnell DD et al. Mobile phone use and risk of tumors: a meta-analysis. J Clin Oncol. 2009;27:5565–72.

    Article  PubMed  Google Scholar 

  7. Deltour I, Johansen C, Auvinen A et al. Time trends in brain tumor incidence rates in Denmark, Finland, Norway, and Sweden, 1974–2003. J Natl Cancer Inst. 2009; 101:1721–24.

    Article  PubMed  Google Scholar 

  8. Louis DN, Ohgaki H, Wiestler OD et al. The 2007 WHO classification of tumors of the central nervous system. Acta Neuropathol. 2007;114:97–109.

    Article  PubMed  Google Scholar 

  9. Houillier C, Lejeune J, Benouaich-Amiel A et al. Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer 2006;106:2218–23.

    Article  CAS  PubMed  Google Scholar 

  10. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57–70.

    Article  CAS  PubMed  Google Scholar 

  11. Furnari FB, Fenton T, Bachoo RM et al. Malignant astrocytic glioma: genetics, biology and paths to treatment. Genes Dev. 2007;21:2683–710.

    Article  CAS  PubMed  Google Scholar 

  12. Phillips HS, Kharbanda S, Chen R et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9:157–73.

    Article  CAS  PubMed  Google Scholar 

  13. Carro MS, Lim WK, Alvarez MJ et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 2010;463:318–25.

    Article  CAS  PubMed  Google Scholar 

  14. Parsons DW, Jones S, Zhang X et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321::1807–12.

    Article  CAS  PubMed  Google Scholar 

  15. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061–68.

    Article  CAS  Google Scholar 

  16. Verhaak RG, Hoadley KA, Purdom E et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities of PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98–110.

    Article  CAS  PubMed  Google Scholar 

  17. Brennan C, Momota H, Hambardzumyan D et al. Glioblastoma subclasses can be defined by activity of signal transduction pathways and associated genomic alterations. PLoS One 2009;4:e7752.

    Article  PubMed  CAS  Google Scholar 

  18. Bredel M, Scholtens DM, Harsh GR et al. A network model of a cooperative genetic landscape in brain tumors. JAMA 2009;302:261–75.

    Article  CAS  PubMed  Google Scholar 

  19. Kleihues P, Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro-oncol 1999;1:44–51.

    CAS  PubMed  Google Scholar 

  20. Tso CL, Freije WA, Day A et al. Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Res. 2006;66:159–67.

    Article  CAS  PubMed  Google Scholar 

  21. Yan H, Parsons DW, Jin G et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765–73.

    Article  CAS  PubMed  Google Scholar 

  22. Sathornsumetee S, Reardon DA, Desjardins A et al. Molecularly targeted therapy for malignant glioma. Cancer 2007;110:13–24.

    Article  PubMed  Google Scholar 

  23. Hoeller D, Dikic I. Targeting the ubiquitin system in cancer therapy. Nature 2009;458:438–44.

    Article  CAS  PubMed  Google Scholar 

  24. Lawler S, Chiocca EA. Emerging functions of microRNAs in glioblastoma. J Neurooncol. 2009;92:297–306.

    Article  CAS  PubMed  Google Scholar 

  25. Barcellos-Hoff MH, Newcomb EW, Zagzag D, Narayana A. Therapeutic targets in malignant glioblastoma microenvironments. Semin Radiat Oncol. 2009;19:163–70.

    Article  PubMed  Google Scholar 

  26. Li Z, Wang H, Eyler CE, Hjelmeland AB, Rich JN. Turning cancer stem cells inside out: an exploration of cancer stem cell signaling pathways. J Biol Chem. 2009;284:16705–09.

    Article  CAS  PubMed  Google Scholar 

  27. Lacroix M, Abi-Said D, Fourney DR et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95:190–98.

    Article  CAS  PubMed  Google Scholar 

  28. McGirt MJ, Chaichana KL, Gathinji M et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg. 2009;110:156–62.

    Article  PubMed  Google Scholar 

  29. Stummer W, Pichlmeier U, Meinel T et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006;7:392–401.

    Article  CAS  PubMed  Google Scholar 

  30. Pichlmeier U, Bink A, Schackert G, Stummer W. ALA Glioma Study Group. Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients. Neuro-oncol 2008;10:1025–34.

    Article  PubMed  Google Scholar 

  31. Wallner KE, Galicich JH, Krol G, Arbit E, Malkin MG. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys. 1989;16:1405–09.

    Article  CAS  PubMed  Google Scholar 

  32. Westphal M, Hilt DC, Bortey E et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncol 2003;5:79–88.

    CAS  PubMed  Google Scholar 

  33. Westphal M, Ram Z, Riddle V, Hilt D, Bortey E. On behalf of the Executive Committee of the Gliadel Study Group. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien). 2006;148:269–75.

    Article  CAS  Google Scholar 

  34. Affronti ML, Heery CR, Herndon JE 2nd et al. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer 2009;115:3501–11.

    Article  CAS  PubMed  Google Scholar 

  35. McGirt MJ, Than KD, Weingart JD et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg. 2009;110:583–88.

    Article  CAS  PubMed  Google Scholar 

  36. Walker MD, Green SB, Byar DP et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980;303:1323–29.

    Article  CAS  PubMed  Google Scholar 

  37. Blumenthal DT, Won M, Mehta MP et al. Short delay in initiation of radiotherapy may not affect outcome of patients with glioblastoma: a secondary analysis from the Radiation Therapy Oncology Group Database. J Clin Oncol. 2009;27:733–39.

    Article  PubMed  Google Scholar 

  38. Lai R, Hershman DL, Doan T, Neugut AI. The timing of cranial radiation in elderly patients with newly diagnosed glioblastoma multiforme. Neuro-oncol 2010;12:190–98.

    PubMed  Google Scholar 

  39. Souhami L, Seiferheld W, Brachman D et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys. 2004;60:853–60.

    Article  PubMed  Google Scholar 

  40. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002;359:1011–18.

    Article  CAS  PubMed  Google Scholar 

  41. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.

    Article  CAS  PubMed  Google Scholar 

  42. Taphoorn MJ, Stupp R, Coens C et al. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol. 2005;6:937–44.

    Article  PubMed  Google Scholar 

  43. Wick W, Hartmann C, Engel C et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol. 2009;27:5874–80.

    Article  CAS  PubMed  Google Scholar 

  44. Stupp R, Hegi ME, Gilbert MR, Chakravarti A. Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol. 2007;25:4127–36.

    Article  CAS  PubMed  Google Scholar 

  45. Mutter N, Stupp R. Temozolomide: a milestone in neuro-oncology and beyond?. Expert Rev Anticancer Ther. 2006;6:1187–204.

    Article  CAS  PubMed  Google Scholar 

  46. Friedman HS, Dolan ME, Pegg AE et al. Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res. 1995;55:2853–57.

    CAS  PubMed  Google Scholar 

  47. Yung WK, Prados MD, Yaya-Tur R et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol. 1999;17:2762–71.

    CAS  PubMed  Google Scholar 

  48. Yung WK, Albright RE, Olson J et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83:588–93.

    Article  CAS  PubMed  Google Scholar 

  49. Friedman HS, McLendon RE, Kerby T et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol. 1998;16:3851–57.

    CAS  PubMed  Google Scholar 

  50. Stupp R, Dietrich PY, Ostermann Kraljevic S et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol. 2002;20:1375–82.

    Article  CAS  PubMed  Google Scholar 

  51. Athanassiou H, Synodinou M, Maragoudakis E et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol. 2005;23:2372–77.

    Article  CAS  PubMed  Google Scholar 

  52. Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–66.

    Article  CAS  PubMed  Google Scholar 

  53. Esteller M. Epigenetics in cancer. N Engl J Med. 2008;358:1148–59.

    Article  CAS  PubMed  Google Scholar 

  54. Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997–1003.

    Article  CAS  PubMed  Google Scholar 

  55. Rivera AL, Pelloski CE, Gilbert MR et al. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro-oncol 2010;12:116–21.

    CAS  PubMed  Google Scholar 

  56. Weller M, Stupp R, Reifenberger G et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine?. Nat Rev Neurol. 2010;6:39–51.

    Article  CAS  PubMed  Google Scholar 

  57. Clarke JL, Iwamoto FM, Sul J et al. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J Clin Oncol. 2009;27:3861–67.

    Article  CAS  PubMed  Google Scholar 

  58. Glas M, Happold C, Rieger J et al. Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. J Clin Oncol. 2009;27:1257–61.

    Article  CAS  PubMed  Google Scholar 

  59. Friedman HS, Dolan ME, Moschel RC et al. Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme. J Natl Cancer Inst. 1992;84:1926–31.

    Article  CAS  PubMed  Google Scholar 

  60. Quinn JA, Desjardins A, Weingart J et al. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol. 2005;23:7178–87.

    Article  CAS  PubMed  Google Scholar 

  61. Quinn JA, Jiang SX, Reardon DA et al. Phase II trial of temozolomide plus O6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol. 2009;27:1262–67.

    Article  CAS  PubMed  Google Scholar 

  62. Quinn JA, Jiang SX, Reardon DA et al. Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. Neuro-oncol 2009;11:556–61.

    Article  CAS  PubMed  Google Scholar 

  63. Clemons M, Kelly J, Watson AJ et al. O6-(4-Bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts. Br J Cancer. 2005;93:1152–56.

    Article  CAS  PubMed  Google Scholar 

  64. Yip S, Miao J, Cahill DP et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res. 2009;15:4622–29.

    Article  CAS  PubMed  Google Scholar 

  65. Cheng CL, Johnson SP, Keir ST et al. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther. 2005;4:1364–68.

    Article  CAS  PubMed  Google Scholar 

  66. Murat A, Migliavacca E, Gorlia T et al. Stem cell-related “self-renewal” signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol. 2008;26:3015–24.

    Article  CAS  PubMed  Google Scholar 

  67. Carson KA, Grossman SA, Fisher JD, Shaw EG. Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol. 2007;25:2601–06.

    Article  PubMed  Google Scholar 

  68. Barnholtz-Sloan JS, Williams VL, Maldonado JL et al. Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma. J Neurosurg. 2008;108:642–48.

    Article  PubMed  Google Scholar 

  69. Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007;356:1527–35.

    Article  CAS  PubMed  Google Scholar 

  70. Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol. 2004;22:1583–88.

    Article  CAS  PubMed  Google Scholar 

  71. Glantz M, Chamberlain M, Liu Q, Litofsky NS, Recht LD. Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer 2003;97:2262–66.

    Article  CAS  PubMed  Google Scholar 

  72. Laigle-Donadey F, Figarella-Branger D, Chinot O et al. Up-front temozolomide in elderly patients with glioblastoma. J Neurooncol. 2010 Jan 8;[Epub ahead of print].

    Google Scholar 

  73. Combs SE, Wagner J, Bischof M et al. Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients. Int J Radiat Oncol Biol Phys. 2008;70:987–92.

    Article  PubMed  Google Scholar 

  74. Kimple RJ, Grabowski S, Papez M, Collichio F, Ewend MG, Morris DE. Concurrent temozolomide and radiation, a reasonable option for elderly patients with glioblastoma multiforme?. Am J Clin Oncol. 2009 Oct 9;[Epub ahead of print].

    Google Scholar 

  75. Brandes AA, Franceschi E, Tosoni A et al. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer 2009;115:3512–18.

    Article  CAS  PubMed  Google Scholar 

  76. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008;9:453–61.

    Article  PubMed  Google Scholar 

  77. de Wit MC, de Bruin HG, Eijkenboom W, Sillevis Smitt PA, van den Bent MJ. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 2004;63:535–37.

    PubMed  Google Scholar 

  78. Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 2008;113:405–10.

    Article  CAS  PubMed  Google Scholar 

  79. Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol. 2008;26:2192–97.

    Article  PubMed  Google Scholar 

  80. Gerstner ER, McNamara MB, Norden AD, Lafrankie D, Wen PY. Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. J Neurooncol. 2009;94:97–101.

    Article  CAS  PubMed  Google Scholar 

  81. Hollingworth W, Medina LS, Lenkinski RE et al. A systematic literature review of magnetic resonance spectroscopy for the characterization of brain tumors. AJNR Am J Neuroradiol. 2006;27:1404–11.

    CAS  PubMed  Google Scholar 

  82. Asao C, Korogi Y, Kitajima M et al. Diffusion-weighted imaging of radiation-induced brain injury for differentiation from tumor recurrence. AJNR Am J Neuroradiol. 2005;26:1455–60.

    PubMed  Google Scholar 

  83. Bastin ME, Carpenter TK, Armitage PA, Sinha S, Wardlaw JM, Whittle IR. Effects of dexamethasone on cerebral perfusion and water diffusion in patients with high-grade glioma. AJNR Am J Neuroradiol. 2006;27:402–08.

    CAS  PubMed  Google Scholar 

  84. Chen W. Clinical applications of PET in brain tumors. J Nucl Med. 2007;48:1468–81.

    Article  PubMed  Google Scholar 

  85. Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999;17:2572–78.

    CAS  PubMed  Google Scholar 

  86. Ballman KV, Buckner JC, Brown PD et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro-oncol 2007;9:29–38.

    Article  CAS  PubMed  Google Scholar 

  87. Lamborn KR, Yung WK, Chang SM et al. Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas. Neuro-oncol 2008;10:162–70.

    Article  PubMed  Google Scholar 

  88. Polley MY, Lamborn KR, Chang SM, Butowski N, Clarke JL, Prados M. Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide. Neuro-oncol 2010;12:274–82.

    CAS  PubMed  Google Scholar 

  89. Butowski NA, Sneed PK, Chang SM. Diagnosis and treatment of recurrent high-grade astrocytoma. J Clin Oncol. 2006;24:1273–80.

    Article  CAS  PubMed  Google Scholar 

  90. Barker FG 2nd, Chang SM, Gutin PH et al. Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery 1998;42:709–20.

    Article  PubMed  Google Scholar 

  91. Guyotat J, Signorelli F, Frappaz D, Madarassy G, Ricci AC, Bret P. Is reoperation for recurrence of glioblastoma justified?. Oncol Rep. 2000;7 4:899–904.

    CAS  PubMed  Google Scholar 

  92. Keles GE, Lamborn KR, Chang SM, Prados MD, Berger MS. Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy. J Neurosurg. 2004;100:41–46.

    Article  PubMed  Google Scholar 

  93. Clarke J, Butowski N, Chang S. Recent advances in therapy for glioblastoma. Arch Neurol. 2010;67:279–83.

    Article  PubMed  Google Scholar 

  94. Brem H, Piantadosi S, Burger PC et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-Brain Tumor Treatment Group. Lancet 1995;345:1008–12.

    Article  CAS  PubMed  Google Scholar 

  95. Metellus P, Coulibaly B, Nanni I et al. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort. Cancer 2009;115:4783–94.

    Article  CAS  PubMed  Google Scholar 

  96. Weingart J, Grossmn ST, Carson KA, Fisher JD, Delaney SM, Rosenblum ML et al. Phase I trial of Polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS Consortium Trial. J Clin Oncol. 2007;25:399–404.

    Article  CAS  PubMed  Google Scholar 

  97. Quinn JA, Jiang SX, Carter J et al. Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. Clin Cancer Res. 2009;15:1064–68.

    Article  CAS  PubMed  Google Scholar 

  98. Vogelbaum MA. Convection enhanced delivery for treating brain tumors and selected neurological disorders: symposium review. J Neurooncol. 2007;83:97–109.

    Article  PubMed  Google Scholar 

  99. Kunwar S, Prados MD, Chang SM et al. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol. 2007;25:837–44.

    Article  CAS  PubMed  Google Scholar 

  100. Sampson JH, Archer G, Pedain C et al. Poor drug distribution as a possible explanation for the results of the PRECISE trial. J Neurosurg. 2009 Dec 18;[Epub ahead of print].

    Google Scholar 

  101. Bauman GS, Sneed PK, Wara WM et al. Reirradiation of primary CNS tumors. Int J Radiat Oncol Biol Phys. 1996;36:433–41.

    Article  CAS  PubMed  Google Scholar 

  102. Combs SE, Widmer V, Thilmann C, Hof H, Debus J, Schulz-Ertner D. Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme (GBM). Cancer 2005;104 10:2168–73.

    Article  PubMed  Google Scholar 

  103. Combs SE, Thilmann C, Edler L, Debus J, Schulz-Ertner D. Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol. 2005;23 34:8863–69.

    Article  PubMed  Google Scholar 

  104. Patel M, Siddiqui F, Jin JY et al. Salvage reirradiation for recurrent glioblastoma with radiosurgery: radiographic response and improved survival. J Neurooncol. 2009;92:185–91.

    Article  PubMed  Google Scholar 

  105. Fokas E, Wacker U, Gross MW, Henzel M, Encheva E, Engenhart-Cabillic R. Hypofractionated stereotactic reirradiation of recurrent glioblastomas: a beneficial treatment option after high-dose radiotherapy?. Strahlenther Onkol. 2009;185:235–40.

    Article  PubMed  Google Scholar 

  106. Tsao MN, Mehta MP, Whelan TJ et al. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma. Int J Radiat Oncol Biol Phys. 2005;63:47–55.

    Article  PubMed  Google Scholar 

  107. Gutin PH, Iwamoto FM, Beal K et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2009;75:156–63.

    Article  CAS  PubMed  Google Scholar 

  108. Reardon DA, Akabani G, Coleman RE et al. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol. 2006;24:115–22.

    Article  CAS  PubMed  Google Scholar 

  109. Reardon DA, Akabani G, Coleman RE et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol. 2002;20:1389–97.

    Article  CAS  PubMed  Google Scholar 

  110. Mamelak AN, Rosenfeld S, Bucholz R et al. Phase I single-dose study of intracavitary-administered iodine-131–TM-601 in adults with recurrent high-grade glioma. J Clin Oncol. 2006;24:3644–50.

    Article  CAS  PubMed  Google Scholar 

  111. Kesavan K, Ratliff J, Johnson EW et al. Annexin A2 is a molecular target for TM601, a peptide with tumor-targeting and anti-angiogenic effects. J Biol Chem. 2010;285:4366–74.

    Article  CAS  PubMed  Google Scholar 

  112. Brandes AA, Tosoni A, Cavallo G et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from Gruppo Italiano Cooperativo di Neuro-oncologia (GICNO). Br J Cancer. 2006;95:1155–60.

    Article  CAS  PubMed  Google Scholar 

  113. Franceschi E, Omuro AM, Lassman AB, Demopoulos A, Nolan C, Abrey LE. Salvage temozolomide for prior temozolomide responders. Cancer 2005;104:2473–76.

    Article  CAS  PubMed  Google Scholar 

  114. Wick A, Pascher C, Wick W et al. Rechallenge with temozolomide in patients with recurrent gliomas. J Neurol. 2009;256:734–41.

    Article  CAS  PubMed  Google Scholar 

  115. Tolcher AW, Gerson SL, Denis L et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer. 2003;88:1004–11.

    Article  CAS  PubMed  Google Scholar 

  116. Wick W, Platten M, Weller M. New (alternative) temozolomide regimens for the treatment of glioma. Neuro-oncol 2009;11:69–79.

    Article  CAS  PubMed  Google Scholar 

  117. Perry JR, Belanger K, Mason WP et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol. 2010 March 22;[E-pub ahead of print].

    Google Scholar 

  118. Newlands ES, Foster T, Zaknoen S. Phase I study of temozolomide (TMZ) combined with procarbazine (PCB) in patients with gliomas. Br J Cancer. 2003;89:248–51.

    Article  CAS  PubMed  Google Scholar 

  119. Prados MD, Yung WK, Fine HA et al. Phase II study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium Study. Neuro-oncol 2004;6:33–37.

    Article  CAS  PubMed  Google Scholar 

  120. Reardon DA, Quinn JA, Rich JN, Desjardins A et al. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer 2005;104:1478–86.

    Article  CAS  PubMed  Google Scholar 

  121. Loghin ME, Prados MD, Wen P et al. Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. Clin Cancer Res. 2007;13:7133–38.

    Article  CAS  PubMed  Google Scholar 

  122. Korones DN, Benita-Weiss M, Coyle TE et al. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma. Cancer 2003;97:1963-68.

    Article  CAS  PubMed  Google Scholar 

  123. Happold C, Roth P, Wick W et al. ACNU-based chemotherapy for recurrent glioma in the temozolomide era. J Neurooncol. 2009;92:45–48.

    Article  CAS  PubMed  Google Scholar 

  124. Wick W, Puduvalli VK, Chamberlain MC et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol. 2010;28:1168–74.

    Article  CAS  PubMed  Google Scholar 

  125. Brandes AA, Tosoni A, Franceschi E et al. Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother Pharmacol. 2009;64:769–75.

    Article  CAS  PubMed  Google Scholar 

  126. Vredenburgh JJ, Desjardins A, Reardon DA, Friedman HS. Experience with irinotecan for the treatment of malignant glioma. Neuro-oncol 2009;11:80–91.

    Article  CAS  PubMed  Google Scholar 

  127. Houghton PJ, Cheshire PJ, Hallman JD 2nd et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol. 1995;36:393–403.

    Article  CAS  PubMed  Google Scholar 

  128. Friedman HS, Petros WP, Friedman AH et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol. 1999;17:1516–25.

    CAS  PubMed  Google Scholar 

  129. Batchelor TT, Gilbert MR, Supko JG et al. Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. Neuro-oncol 2004;6:21–27.

    Article  CAS  PubMed  Google Scholar 

  130. Prados MD, Lamborn K, Yung WK et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium Study. Neuro-oncol 2006;8:189–93.

    Article  CAS  PubMed  Google Scholar 

  131. Sigmond J, Honeywell RJ, Postma TJ et al. Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer. Ann Oncol. 2009;20:182–87.

    Article  CAS  PubMed  Google Scholar 

  132. Metro G, Fabi A, Mirri MA et al. Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme. Cancer Chemother Pharmacol. 2010;65:391–97.

    Article  CAS  PubMed  Google Scholar 

  133. Aoki T, Mizutani T, Nojima K et al. Phase II study of ifosfamide, carboplatin, and etoposide in patients with a first recurrence of glioblastoma multiforme. J Neurosurg. 2010;112:50–56.

    Article  CAS  PubMed  Google Scholar 

  134. Durando X, Lemaire JJ, Tortochaux J et al. High-dose BCNU followed by autologous hematopoietic stem cell transplantation in supratentorial high-grade malignant gliomas: a retrospective analysis of 114 patients. Bone Marrow Transplant. 2003;31:559–64.

    Article  CAS  PubMed  Google Scholar 

  135. Madajewicz S, Chowhan N, Tfayli A et al. Therapy for patients with high grade astrocytoma using intraarterial chemotherapy and radiation therapy. Cancer 2000;88:2350–56.

    Article  CAS  PubMed  Google Scholar 

  136. Bleau AM, Huse JT, Holland EC. The ABCG2 resistance network of glioblastoma. Cell Cycle 2009;8:2936–44.

    PubMed  Google Scholar 

  137. Sathornsumetee S, Rich JN. Designer therapies for glioblastoma multiforme. Ann N Y Acad Sci. 2008;1142:108–32.

    Article  CAS  PubMed  Google Scholar 

  138. Rich JN, Reardon DA, Peery T et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol. 2004;22:133–42.

    PubMed  Google Scholar 

  139. Franceschi E, Cavallo G, Lonardi S et al. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer. 2007;96:1047–51.

    Article  CAS  PubMed  Google Scholar 

  140. van den Bent MJ, Brandes AA, Rampling R et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC Brain Tumor Group Study 26034. J Clin Oncol. 2009;27:1268–74.

    Article  PubMed  CAS  Google Scholar 

  141. Raizer JJ, Abrey LE, Lassman AB et al. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro-oncol 2010;12:95–103.

    CAS  PubMed  Google Scholar 

  142. deGroot JF, Gilbert MR, Aldape K et al. Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. J Neurooncol. 2008;90:89–97.

    Article  CAS  Google Scholar 

  143. Brown PD, Krishnan S, Sarkaria JN et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol. 2008;26:5603–09.

    Article  CAS  PubMed  Google Scholar 

  144. Prados MD, Chang SM, Butowski N et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol. 2009;27:579–84.

    Article  CAS  PubMed  Google Scholar 

  145. Peereboom DM, Shepard DR, Ahluwalia MS et al. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol. 2009 Dec 4.;[Epub ahead of print].

    Google Scholar 

  146. Neyns B, Sadones J, Joosens E et al. Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann Oncol. 2009;20:1596–603.

    Article  CAS  PubMed  Google Scholar 

  147. Cloughesy TF, Wen PY, Robins HI et al. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol. 2006;24:3651–56.

    Article  CAS  PubMed  Google Scholar 

  148. Wen PY, Yung WK, Lamborn KR et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res. 2006;12:4899–907.

    Article  CAS  PubMed  Google Scholar 

  149. Raymond E, Brandes AA, Dittrich C et al. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol. 2008;26:4659–65.

    Article  CAS  PubMed  Google Scholar 

  150. Reardon DA, Egorin MJ, Quinn JA et al. Phase 2 study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol. 2005;23:9359–68.

    Article  CAS  PubMed  Google Scholar 

  151. Desjardins A, Quinn JA, Vredenburgh JJ et al. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol. 2007;83:53–60.

    Article  CAS  PubMed  Google Scholar 

  152. Reardon DA, Dresemann G, Taillibert S et al. Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br J Cancer. 2009;101:1995–2004.

    Article  CAS  PubMed  Google Scholar 

  153. Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol. 2005;23:5294–304.

    Article  CAS  PubMed  Google Scholar 

  154. Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs. 2005;23 4:357–61.

    Article  CAS  PubMed  Google Scholar 

  155. Kreisl TN, Kotliarova S, Butman JA et al. A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. Neuro-oncol 2010;12:181–89.

    CAS  PubMed  Google Scholar 

  156. Reardon DA, Fink KL, Mikkelsen T et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol. 2008;26:5610–17.

    Article  CAS  PubMed  Google Scholar 

  157. Galanis E, Jaeckle KA, Maurer MJ et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol. 2009;27:2052–58.

    Article  CAS  PubMed  Google Scholar 

  158. Stommel JM, Kimmelman AC, Ying H et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007;318:287–90.

    Article  CAS  PubMed  Google Scholar 

  159. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031–37.

    Article  CAS  PubMed  Google Scholar 

  160. Wen PY, Kesari S, Drappatz J. Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment. Expert Rev Anticancer Ther. 2006;6 5:733–54.

    Article  CAS  PubMed  Google Scholar 

  161. Sathornsumetee S, Reardon DA. Targeting multiple kinases in glioblastoma multiforme. Expert Opin Investig Drugs. 2009;18:277–92.

    Article  CAS  PubMed  Google Scholar 

  162. Reardon DA, Quinn JA, Vredenburgh JJ et al. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res. 2006;12:860–68.

    Article  CAS  PubMed  Google Scholar 

  163. Chang SM, Kuhn J, Lamborn K et al. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas (MG) (NABTC 04-02).Proc Am Soc Clin Oncol. 2009;27 15 s:(abstract 2004).

    Google Scholar 

  164. Prados M, Gilbert M, Kuhn J et al. Phase I/II study of sorafenib and erlotinib for patients with recurrent glioblastoma (GBM) (NABTC 05-02).Proc Am Soc Clin Oncol. 2009;27 15 s:(abstract 2005).

    Google Scholar 

  165. Wen PY, Cloughesy T, Kuhn J et al. Phase I/II study of erlotinib and temsirolimus for patients with recurrent glioblastoma (GBM) (NABTC 05-02).Proc Am Soc Clin Oncol. 2009;27 15 s:(abstract 2006).

    Google Scholar 

  166. Chang SM, Lamborn KR, Kuhn JG et al. Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. Neuro-oncol 2008;10:631–42.

    Article  PubMed  Google Scholar 

  167. Williams KJ, Telfer BA, Brave S et al. ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity. Clin Cancer Res. 2004;10:8587–93.

    Article  CAS  PubMed  Google Scholar 

  168. Haas-Kogan DA, Prados MD, Tihan T et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst. 2005;97:880–87.

    Article  CAS  PubMed  Google Scholar 

  169. Mellinghoff IK, Wang MY, Vivanco I et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005;353:2012–24.

    Article  CAS  PubMed  Google Scholar 

  170. Cloughesy TF, Yoshimoto K, Nghiemphu P et al. Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 2008;5:e8.

    Article  PubMed  CAS  Google Scholar 

  171. Mathieu V, De Nève N, Le Mercier M et al. Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia 2008;10:1383–92.

    CAS  PubMed  Google Scholar 

  172. Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma.Neuro-oncol. 2005;7 369 :(abstract 342).

    Google Scholar 

  173. Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25:4722–29.

    Article  CAS  PubMed  Google Scholar 

  174. Wagner SA, Desjardins A, Reardon DA et al. Update on survival from the original phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas. Proc Am Soc Clin Oncol. 2008;26:(abstract 2021).

    Google Scholar 

  175. Kreisl TN, Kim L, Moore K et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27:740–45.

    Article  CAS  PubMed  Google Scholar 

  176. Norden AD, Young GS, Setayesh K et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008;70:779–87.

    Article  CAS  PubMed  Google Scholar 

  177. Bokstein F, Shpigel S, Blumenthal DT. Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer 2008;112:2267–73.

    Article  CAS  PubMed  Google Scholar 

  178. Kang TY, Jin T, Elinzano H et al. Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety. J Neurooncol. 2008;89:113–18.

    Article  CAS  PubMed  Google Scholar 

  179. Ali SA, McHayleh WM, Ahmad A et al. Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases. J Neurosurg. 2008;109:268–72.

    Article  CAS  PubMed  Google Scholar 

  180. Narayana A, Kelly P, Golfinos J et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg. 2009;110:173–80.

    Article  PubMed  Google Scholar 

  181. Zuniga RM, Torcuator R, Jain R et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab and irinotecan. J Neurooncol. 2009;91:329–36.

    Article  CAS  PubMed  Google Scholar 

  182. Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733–40.

    Article  CAS  PubMed  Google Scholar 

  183. Wick W, Weller M, van den Bent M, Stupp R. Bevacizumab and recurrent malignant gliomas: a European perspective. J Clin Oncol. 2010 Mar 8;[Epub ahead of print].

    Google Scholar 

  184. Wen PY, Macdonald DR, Reardon DA et al. Updated response assessment criteria for high-grade gliomas: response assessment in Neuro-Oncology Working Group. J Clin Oncol. 2010 Mar 15;[Epub ahead of print].

    Google Scholar 

  185. Desjardins A, Reardon DA, Herndon JE 2nd et al. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res. 2008;14:7068–73.

    Article  CAS  PubMed  Google Scholar 

  186. Reardon DA, Desjardins A, Vredenburgh JJ et al. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer. 2009;101:1986–94.

    Article  CAS  PubMed  Google Scholar 

  187. Sathornsumetee S, Desjardins A, Vredenburgh JJ et al. Phase II study of bevacizumab plus erlotinib for recurrent malignant gliomas.Proc Am Soc Clin Oncol. 2009;27 15 s:(Abstract 2045).

    Google Scholar 

  188. De Groot JF, Wen PY, Lamborn K et al. Phase II single arm trial of aflibercept in patients with recurrent temozolomide-resistant glioblastoma: NABTC 0601. Proc Am Soc Clin Oncol. 2008;26:(abstract 2020).

    Google Scholar 

  189. Batchelor TT, Sorensen AG, di Tomaso E et al. AZD2171, a Pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11:83–95.

    Article  CAS  PubMed  Google Scholar 

  190. Iwamoto FM, Lamborn JR, Robins HI et al. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro-oncol 2010 March 3;[Epub ahead of print].

    Google Scholar 

  191. de Groot JF, Prados M, Urquhart T et al. A phase II study of XL 184 in patients (pts) with progressive glioblastoma multiforme (GBM) in first or second relapse.Proc Am Soc Clin Oncol. 2009;27 15 s:(Abstract 2047).

    Google Scholar 

  192. Neyns B, Chaskis C, Dujardin M et al. Phase II trial of sunitinib malate in patients with temozolomide refractory recurrent high-grade glioma.Proc Am Soc Clin Oncol. 2009;27 15 s:(Abstract 2038).

    Google Scholar 

  193. Chamberlain MC, Johnston S. Salvage chemotherapy with bevacizumab for recurrent alkylator refractory anaplastic astrocytoma. J Neurooncol. 2009;91:359–67.

    Article  CAS  PubMed  Google Scholar 

  194. Kamoun WS, Ley CD, Farrar CT et al. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol. 2009;27:2542–52.

    Article  CAS  PubMed  Google Scholar 

  195. Quant EC, Norden AD, Drappatz J et al. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro-oncol 2009;11:550–55.

    Article  CAS  PubMed  Google Scholar 

  196. Scott BJ, Quant EC, McNamara MB, Ryg PA, Batchelor TT, Wen PY. Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. Neuro-oncol 2010 Feb 14;[Epub ahead of print].

    Google Scholar 

  197. Chen W, Delaloye S, Silverman DH et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. 2007;25:4714–21.

    Article  CAS  PubMed  Google Scholar 

  198. Sathornsumetee S, Cao Y, Marcello JE et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol. 2008;26:271–78.

    Article  CAS  PubMed  Google Scholar 

  199. Nghiemphu PL, Liu W, Lee Y et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 2009;72:1217–22.

    Article  CAS  PubMed  Google Scholar 

  200. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8:592–603.

    Article  CAS  PubMed  Google Scholar 

  201. Pàez-Ribes M, Allen E, Hudock J et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220–31.

    Article  PubMed  CAS  Google Scholar 

  202. Ebos JM, Lee CR, Cruz-Munoz W et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232–39.

    Article  CAS  PubMed  Google Scholar 

  203. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10:9–22.

    Article  CAS  PubMed  Google Scholar 

  204. Mikkelsen T, Brodie C, Finniss S et al. Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. Int J Cancer. 2009;124:2719–27.

    Article  CAS  PubMed  Google Scholar 

  205. Stupp R, Goldbrunner R, Neyns B et al. Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients (pts) with newly diagnosed glioblastoma (GBM).Proc Am Soc Clin Oncol. 2007;25 18 s:(Abstract 2000).

    Google Scholar 

  206. Nabors LB, Mikkelsen T, Batchelor T et al. NABTT 0306: a randomized phase II trial of EMD 121974 in conjunction with concomitant and adjuvant temozolomide with radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM).Proc Am Soc Clin Oncol. 2009;27 15 s:(Abstract 2001).

    Google Scholar 

  207. Piao Y, Lu L, de Groot J. AMPA receptors promote perivascular glioma invasion via beta1 integrin-dependent adhesion to the extracellular matrix. Neuro-oncol 2009;11:260–73.

    Article  CAS  PubMed  Google Scholar 

  208. Grossman SA, Ye X, Chamberlain M et al. Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial. J Clin Oncol. 2009;27:4155–61.

    Article  CAS  PubMed  Google Scholar 

  209. Iwamoto FM, Kreisl TN, Kim L et al. Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas. Cancer 2010 Feb 8;[Epub ahead of print].

    Google Scholar 

  210. Conley BA, Wright JJ, Kummar S. Targeting epigenetic abnormalities with histone deacetylase inhibitors. Cancer 2006;107:832–40.

    Article  CAS  PubMed  Google Scholar 

  211. Mani A, Gelmann EP. The ubiquitin–proteasome pathway and its role in cancer. J Clin Oncol. 2005;23:4776–89.

    Article  CAS  PubMed  Google Scholar 

  212. Koschny R, Holland H, Sykora J et al. Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clin Cancer Res. 2007;13:3403–12.

    Article  CAS  PubMed  Google Scholar 

  213. Phuphanich S, Supko JG, Carson KA et al. Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma. J Neurooncol. 2010 Mar 8;[Epub ahead of print].

    Google Scholar 

  214. Lesniak MS. Gene therapy for malignant glioma. Expert Rev Neurother. 2006;6:479–88.

    Article  CAS  PubMed  Google Scholar 

  215. Terzis AJ, Niclou SP, Rajcevic U, Danzeisen C, Bjerkvig R. Cell therapies for glioblastoma. Expert Opin Biol Ther. 2006;6:739–49.

    Article  CAS  PubMed  Google Scholar 

  216. Han SJ, Kaur G, Yang I, Lim M. Biologic principles of immunotherapy for malignant gliomas. Neurosurg Clin N Am. 2010;21:1–16.

    Article  PubMed  Google Scholar 

  217. Heimberger AB, Crotty LE, Archer GE et al. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res. 2003;9:4247–54.

    CAS  PubMed  Google Scholar 

  218. Kirson ED, Dbalý V, Tovarys F et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci USA. 2007;104:10152–57.

    Article  CAS  PubMed  Google Scholar 

  219. Potti A, Dressman HK, Bild A et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med. 2006;12:1294–300.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine (Neurology), Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

    Sith Sathornsumetee

  2. Departments of Surgery and Pediatrics, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, 27710, USA

    David A. Reardon

Authors
  1. Sith Sathornsumetee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David A. Reardon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Sith Sathornsumetee or David A. Reardon .

Editor information

Editors and Affiliations

  1. Dana-Farber Cancer Institute, Harvard Medical School, Binney St. 44, Boston, 02115, Massachusetts, USA

    Andrew D. Norden

  2. Departments of Surgery and Pediatrics, Duke University Medical Center, Durham, 27710, North Carolina, USA

    David A. Reardon

  3. Dana-Farber Cancer Institute, Harvard Medical School, Binney St. 44, Boston, 02115, Massachusetts, USA

    Patrick C. Y. Wen

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Sathornsumetee, S., Reardon, D.A. (2011). High-Grade Astrocytomas. In: Norden, A., Reardon, D., Wen, P. (eds) Primary Central Nervous System Tumors. Current Clinical Oncology. Humana Press. https://doi.org/10.1007/978-1-60761-166-0_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-166-0_9

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60761-165-3

  • Online ISBN: 978-1-60761-166-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation